Ten years ago within the Munich Business Plan Challenge an idea named “hepacult” was nominated, that has been realized in 2002 with the official establishment of our enterprise. Since then the usage of human cells in medical research and development has not only well-established, the testing of drugs and agents with human cells or tissue has beyond that developed a new “gold standard”.

We are proud that we could contribute substantially to this development with our services linked to the research of our customers. Content customers and the resulting positive performance of our company allowed us to support the centers of liver cell research at the University hospitals of Regensburg and Munich. With this cooperation lot of academic research projects could already be accomplished.

This experts‘ forum as meeting exclusively for invited participants has given the unique opportunity to get to know more closely the enlarged hepacult-team as well most of our customers and partners. Thereby sharing experiences with other users of human cells or tissue was the main focus.

1. Ten years hepacult – businessplan and sucessful realization

1. Welcome and presentation of the enlarged hepacult-team
   Kurt Martin, Managing Partner hepacult GmbH
2. Idea, foundation and creation of the necessary framework
   Werner Arndt, Geschäftsführer MBPW GmbH
   PD Dr. Wolfgang Thasler und PD Dr. Thomas Weiß, founder and partner hepacult GmbH
   Prof. Dr. Karl-Walter Jauch/Dr. Thomas Plän, foundation HTCR
   Prof. Horst Domdey, Director BioM Biotech Cluster Development GmbH

2. Proven and new ways of human cell based research- hepacult mirrored by its customers and partners

1. On the use of human liver cells (in-vitro-model of the liver) teams of the following pharmaceutical companies gave reports:
   
   • BayerSchering AG
   • Boeringer-Ingelheim Pharma GmbH&Co. KG
   • Daiichi Sankyo Europe GmbH
   • F. Hoffmann-La Roche Ltd.
     und von Forschungsgruppen der
   • TU München
   • LMU München
   • Universitätsklink Regensburg
   • Universität Heidelberg
   • Eberhard-Karls-Universität Tübingen
     
   as well as from following scientific service providers:
   • Bisoservice Scientific Laboratories GmbH
   • Primacyt GmbH
2. On the developement of in-vitro systems of other organs (fat tissue, thyroid, intestine/kidney, skin) were talking researchers from
   
   • TU Munich
   as well as from the pharmaceutical companies:
   • Daiichi Sankyo Europe GmbH
   • F. Hoffmann La Roche Ltd.
   • Hexal AG

View latest detailed program (pdf-file, German only)


View press information (short version, pdf-file)